BEIGENE, LTD.

(BGNE)
  Bericht
Realtime-Estimate Cboe BZX  -  21:42 01.07.2022
166.74 USD   +3.02%
30.06.Novartis-Mittel Tislelizumab lässt Speiseröhrenkrebs-Patienten länger leben
AW
30.06.BeiGene gibt auf der ESMO GI bahnbrechende Daten bekannt, die den Vorteil von Tislelizumab plus Chemotherapie bei der Erstbehandlung des fortgeschrittenen oder metastasierten Plattenepithelkarzinoms des Ösophagus zeigen
CI
27.06.BeiGene vergibt Aktienoptionen und Restricted Share Units
MT
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivate 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News
Nachrichten in anderen Sprachen über BEIGENE, LTD.
30.06.BEIGENE : Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tis..
30.06.BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
30.06.Novartis livre des indications sur le tislélizumab en oncologie
30.06.BeiGene Says Esophageal Cancer Combination Therapy Improved Overall Survival in Phase 3..
30.06.BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Ti..
30.06.BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Ti..
27.06.BeiGene Grants Share Options, Restricted Share Units
27.06.Antengene Corporation Limited Announces Clinical Trial Collaboration with BeiGene, Ltd...
24.06.Asian ADRs Climb Higher in Friday Trading
23.06.BEIGENE : Announces Acceptance of Supplemental Biologics License Application in China for ..
22.06.INSIDER SELL : Beigene
22.06.INSIDER SELL : Beigene
22.06.BEIGENE, LTD. : Change in Directors or Principal Officers, Submission of Matters to a Vote..
22.06.Beigene, Ltd. Announces Executive Changes
21.06.European ADRs Rise Sharply in Tuesday Trading
21.06.SECTOR UPDATE : Health Care Stocks Edge Higher Premarket Tuesday
21.06.BeiGene Says China Regulators Accept Supplemental Biologics License Application for Ant..
21.06.BeiGene Announces Acceptance of Supplemental Biologics License Application in China for..
21.06.Beigene Announces Acceptance of Supplemental Biologics License Application in China for..
15.06.Certain Options of BeiGene, Ltd. are subject to a Lock-Up Agreement Ending on 15-JUN-20..
15.06.Certain Restricted Share Units of BeiGene, Ltd. are subject to a Lock-Up Agreement Endi..
15.06.Certain A Shares of BeiGene, Ltd. are subject to a Lock-Up Agreement Ending on 15-JUN-2..
14.06.BEIGENE : Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at ..
14.06.BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
14.06.TRANSCRIPT : BeiGene, Ltd. Presents at Goldman Sachs 43rd Annual Global Healthcare Confere..
14.06.FDA Extends PDUFA Goal Date for BeiGene Drug to January 2023; Shares Slip 5.67%
13.06.SECTOR UPDATE : Health Care Stocks Slip Premarket Monday
13.06.BeiGene's Lymphoma Treatment Approved in Kuwait, Bahrain and Qatar
13.06.BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets
13.06.Ministry of Health in Kuwait Approves Beigene, Ltd.'s BRUKINSA™ (Zanubrutinib) in ..
13.06.BeiGene Says US FDA Extends Fee Act for Supplementary New Drug Application for Brukinsa
13.06.BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatmen..
13.06.Beigene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatmen..
10.06.Asian ADRs Move Sharply Lower in Friday Trading
10.06.SECTOR UPDATE : Health Care Stocks Lean Lower Pre-Bell Friday
10.06.BeiGene Secures China's Approval for Tislelizumab Treatment for Nasopharyngeal Cancer; ..
10.06.BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at..
10.06.China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer
10.06.BeiGene, Ltd. Announces NMPA Grants its Anti-PD-1 Antibody Tislelizumab Approval for Fi..
10.06.BeiGene Gets China OK of Tislelizumab in Nasopharyngeal Cancer
08.06.BeiGene to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
27.05.BEIGENE : Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and G..
27.05.BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
26.05.BeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and ..
24.05.Asian ADRs Move Lower in Tuesday Trading
17.05.BeiGene to Open Regional Office in Switzerland
17.05.BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Swi..
17.05.BeiGene, Ltd. Announces the Opening of a New Regional Office in Basel, Switzerland
12.05.BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hemato..
11.05.Asian ADRs Move Higher in Wednesday Trading
10.05.Asian ADRs Climb Higher in Tuesday Trading
09.05.INSIDER SELL : BeiGene
09.05.BEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results ..
05.05.BeiGene Swings to Q1 Net Loss as Revenue Declines
05.05.Earnings Flash (BGNE) BEIGENE Reports Q1 Revenue $306.6M, vs. Street Est of $300.4M
05.05.BEIGENE, LTD. : Results of Operations and Financial Condition, Other Events, Financial Sta..
05.05.BeiGene Reports First Quarter 2022 Financial Results
05.05.BeiGene, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
04.05.BeiGene Says China Gives Conditional Approval to Blincyto Injection for Pediatric Acute..
04.05.BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for P..
04.05.Beigene Announces the Approval in China of BLINCYTO® for Injection for Pediatric Patien..
29.04.BeiGene Breaks Ground on Flagship US Facility in New Jersey; Shares Climb
29.04.BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton Wes..
29.04.Beigene Breaks Ground on New Manufacturing and Clinical R&D Center At the Princeton Wes..
29.04.BEIGENE : Financial Information - Form 8-K
28.04.BEIGENE, LTD. : Results of Operations and Financial Condition, Other Events, Financial Sta..
28.04.BeiGene's Brukinsa Secures Uruguay's Approval For Lymphoma, Waldenstrom's Macroglobulin..
28.04.BeiGene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, ..
28.04.Beigene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, ..
27.04.BeiGene, Ltd. Announces Global Phase 3 Trial of PD-1 Inhibitor, Tislelizumab, in Combin..
27.04.BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual..
27.04.BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual..
27.04.NOVARTIS : résultats d'une étude pour le tislelizumab
27.04.Global Phase 3 Trial of BeiGene's PD-1 Inhibitor, Tislelizumab, in Combination with Che..
27.04.BeiGene Phase 3 Trial for Tislelizumab Meets Primary Endpoint
1  2  3  4  5  6  7  8  9  10Weiter